Olutasidenib Clinical Trials
10 recruitingDrug
Phase 28Phase 12Phase 41
Showing 1–10 of 10 trials
Recruiting
Phase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid LeukemiaMyelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+2 more
National Cancer Institute (NCI)2,000 enrolled346 locationsNCT05564390
Recruiting
Phase 2
Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy
Acute Myeloid LeukemiaIDH1 Mutation
Justin Watts, MD16 enrolled1 locationNCT06782542
Recruiting
Phase 2
A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center45 enrolled1 locationNCT06597734
Recruiting
Phase 2
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Targeted TherapyIDH1-Mutated MalignanciesMutations
M.D. Anderson Cancer Center68 enrolled1 locationNCT07032727
Recruiting
Phase 1Phase 2
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
Mutant IDH1 Inhibitor Olutasidenib
M.D. Anderson Cancer Center78 enrolled2 locationsNCT06445959
Recruiting
Phase 4
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
CholangiocarcinomaSolid Tumor MalignanciesGlioma+1 more
Rigel Pharmaceuticals16 enrolled2 locationsNCT07486713
Recruiting
Phase 2
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Acute Myeloid Leukemia
University of California, Davis28 enrolled1 locationNCT07304011
Recruiting
Phase 1
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia
City of Hope Medical Center15 enrolled2 locationsNCT06543381
Recruiting
Phase 2
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance
M.D. Anderson Cancer Center15 enrolled1 locationNCT06566742
Recruiting
Phase 2
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
Myeloid Malignancies
M.D. Anderson Cancer Center31 enrolled1 locationNCT06668584